

## SCORING OF OBJECTIVE CRITERIA

<b>Table 1: New Drug Category: Scoring Criteria</b>	<b>Score</b>
1. Does the nominated drug have a pediatric indication in a trusted foreign jurisdiction that includes the neonates (term +/- preterm)	<b>Yes: 1 / No: 0</b>
2. Does this product specifically address the unique needs of Indigenous people in Canada <sup>1</sup> ?	<b>Yes: 1 / No: 0</b>
3. Is this drug on the <a href="#">WHO Model List of Essential medicines for Children</a> (9th list, 2023)?	<b>Yes: 1 / No: 0</b>
4. Is this product regularly requested through <a href="#">Health Canada Special Access Program</a> (i.e. appears in the SAP Top 30)?	<b>Yes: 1 / No: 0</b>

Maximum score = 4; Minimum score = 0

<sup>1</sup> An expert panel was put together to look at the NPLPD and provide their perspective on the unique needs in this community.

<b>Table 2: New Indication Category: Scoring Criteria</b>	<b>Score</b>
1. Does the nominated drug have a pediatric indication in a trusted foreign jurisdiction that includes the neonates (term +/- preterm) ?”	<b>Yes: 1 / No: 0</b>
2. Does this product specifically address the unique needs of Indigenous people in Canada <sup>1</sup> ?	<b>Yes: 1 / No: 0</b>
3. Does the lack of indication for this product interfere with adherence, or negatively impact patient’s sense of safety? The score is based on the respondent’s answers to Question 3 of the <a href="#">nomination form</a> .	<b>Yes: 1 / No: 0</b>
4. Do the current gaps in labelling impede appropriate reimbursement and access to the product as currently marketed? The score is based on the respondent’s answers to Question 3 of the <a href="#">nomination form</a> and includes Manufacturer Access program.	<b>Yes: 1 / No: 0</b>
5. Does this drug appear in the CIHI (Canadian Institute for Health Information) Top 80 most commonly prescribed drugs list?	<b>Yes: 1 / No: 0</b>

Maximum score = 5; Minimum score = 0

<sup>1</sup> An expert panel was put together to look at the NPLPD and provide their perspective on the unique needs in this community.

<b>Table 3: New Formulation and New Indication and Formulation Categories: Scoring Criteria</b>	<b>Score</b>
1. Does the nominated drug have a pediatric indication in a trusted foreign jurisdiction that includes the neonates (term +/- preterm) ?”	<b>Yes: 1 / No: 0</b>
2. Does this product specifically address the unique needs of Indigenous people in Canada <sup>1</sup> ?	<b>Yes: 1 / No: 0</b>
3. Is this drug on the <a href="#">WHO Model List of Essential medicines for Children</a> (9th list, 2023)?	<b>Yes: 1 / No: 0</b>
4. Is this product regularly requested through <a href="#">Health Canada Special Access Program</a> (i.e. appears in the SAP Top 30)?	<b>Yes: 1 / No: 0</b>
5. Is this drug known to have a Narrow Therapeutic Index (as per <a href="#">DrugBank Online</a> )?	<b>Yes: 1 / No: 0</b>
6. Is this drug considered a high alert medication (as per <a href="#">ISMP criteria</a> )?	<b>Yes: 1 / No: 0</b>
7. Does this drug currently require compounding by pharmacists or manipulation by HCP or caregivers to be administered to children? The score is based on the respondent’s answers to Question 3 of the <a href="#">nomination form</a> AND by consulting the following references: <a href="#">Hospital for Sick Kids</a> and <a href="#">CHUSJ</a>	<b>Yes: 1 / No: 0</b>
8. Do the current gaps in labelling impede appropriate reimbursement and access to the product as currently marketed? The score is based on the respondent’s answers to Question 3 of the <a href="#">nomination form</a> and includes Manufacturer Access program.	<b>Yes: 1 / No: 0</b>
9. Does this drug require complex compounding i.e. considered as an hazardous drugs (HD) ( <a href="#">NIOSH list</a> ), short stability (SS) defined 14 days or less, or more than 2 ingredients?	<b>Yes: 1 / No: 0</b>
10. Does the currently compounded product or commercially available formulation have well known/recognized adherence issues (taste, volume, adverse event or other)? The score is based on CHUSJ pharmacy department pharmacists evaluation.	<b>Yes: 1 / No: 0</b>
11. Does this drug appear in the CIHI (Canadian Institute for Health Information) Top 80 most commonly prescribed drugs list?	<b>Yes: 1 / No: 0</b>
12. Does this drug appear in the GPFC list of Top 20 commonly compounded drugs (as per the publication by <a href="#">Litalien et al.</a> )?	<b>Yes: 1 / No: 0</b>

Maximum score = 12; Minimum score = 0

<sup>1</sup> An expert panel was put together to look at the NPLPD and provide their perspective on the unique needs in this community.